Phase I/II Trial of Dexamethasone, Ofatumumab and Bendamustine [Treanda] (DOT) as First-line Treatment of Mantle-cell Lymphoma (MCL) in the Elderly.

Trial Profile

Phase I/II Trial of Dexamethasone, Ofatumumab and Bendamustine [Treanda] (DOT) as First-line Treatment of Mantle-cell Lymphoma (MCL) in the Elderly.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Bendamustine (Primary) ; Dexamethasone (Primary) ; Ofatumumab (Primary)
  • Indications Mantle-cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Dec 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 15 Mar 2012 Actual initiation date changed from Apr 2010 to 2 Dec 2009 as reported by European Clinical Trials Database.
    • 10 Dec 2011 Interim results have been reported at the 53rd Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top